Recommendations for rheumatologists on pharmacological management during the COVID-19 health emergency: Expert group opinion()

Coronavirus 2019 (COVID-19) is an unexpected pandemic that has caused a state of emergency, as well as generating drastic changes in clinical care protocols. Some drugs commonly used in rheumatoid arthritis, systemic lupus erythematosus, and other systemic autoimmune diseases have been described for...

Descripción completa

Detalles Bibliográficos
Autores principales: López, Josué-Guillermo, Camacho-Barbosa, Jhyld-Carolaind, Felipe-Díaz, Oscar-Jair, Rojas-Zuleta, Wilmer-Gerardo, Ballesteros, Jesús-Giovanny, Navarro-Mendoza, Erika-Paola, Giraldo Herrera, Claudia-Lucía, Giraldo-Bustos, Rodrigo, Padilla-Tovar, Lácides, Duque-Zapata, Natalia, Orozco González, Catalina, López-Mora, María-José, Donado, Jorge-Hernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. 2021
Materias:
Reflexion Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041268/
http://dx.doi.org/10.1016/j.rcreue.2020.05.009
Descripción
Sumario:Coronavirus 2019 (COVID-19) is an unexpected pandemic that has caused a state of emergency, as well as generating drastic changes in clinical care protocols. Some drugs commonly used in rheumatoid arthritis, systemic lupus erythematosus, and other systemic autoimmune diseases have been described for its treatment. Therefore, there is an imminent risk of shortages. The aim of this narrative review and expert opinion is to present general recommendations on the clinical and administrative management of outpatients with autoimmune or systemic inflammatory disease, in the context of the COVID-19 pandemic.

Ejemplares similares